Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

Long-term efficacy and safety of guselkumab in Chinese patients with moderate-to-severe plaque psoriasis

BackgroundRandomized controlled trials indicated guselkumab, the first anti-interleukin-23 monoclonal antibody, is efficacious in plaque psoriasis. However, guselkumab's performance in real life is scarcely examined, especially in China.ObjectivesThis work aimed to assess the long-term effectiv...

Full description

Bibliographic Details
Main Authors: Jianfeng Zheng, Wenjuan Chen, Xuemei Yi, Ning Yu, Yangfeng Ding, Yunlu Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-12-01
Series:Frontiers in Medicine
Subjects:
Chinese patients
efficacy
guselkumab
plaque psoriasis
real-life
safety
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1285972/full

Similar Items

Similar Items